Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JDB153 Combined With Serplulimab in Refractory Pancreatic Cancer
NCT07175389Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Sep 2026
- Primary completion
- Sep 2028
- Countries
- 1
01
Overview
A Phase 2 trial of JDB153 in pancreatic cancer (PC), sponsored by West China Hospital of Sichuan University. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
JDB153
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT07175389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07175389.